Article: [Unclear hepatopathy in a patient with atrial fibrillation]

Although liver damage is a relatively rare adverse effect of oral anticoagulation with phenprocoumon, acute liver failure can be a serious treatment-associated complication. In this contribution, a patient with drug-induced liver failure during oral anticoagulation with phenprocoumon is presented. This case illustrates the need for close laboratory monitoring and suggests that phenrocoumon-induced liver damage should be considered along with other common complications of this treatment.

Citing Articles

Bleeding complications and liver injuries during phenprocoumon treatment: a multicentre prospective observational study in internal medicine departments.

Schmiedl S, Rottenkolber M, Szymanski J, Siegmund W, Hippius M, Farker K Dtsch Arztebl Int. 2013; 110(14):244-52.

PMID: 23616817 PMC: 3632811. DOI: 10.3238/arztebl.2013.0244.

[Role of vitamin K antagonists from a hepatologist's point of view].

Kneiseler G, Canbay A, Gerken G Herz. 2012; 37(4):395-401.

PMID: 22539098 DOI: 10.1007/s00059-012-3620-2.

References

1.

Schimanski C, Burg J, Mohler M, Hohler T, Kanzler S, Otto G . Phenprocoumon-induced liver disease ranges from mild acute hepatitis to (sub-) acute liver failure. J Hepatol. 2004; 41(1):67-74. DOI: 10.1016/j.jhep.2004.03.010. View

2.

Hohler T, Schnutgen M, Helmreich-Becker I, Mayet W, Mayer zum Buschenfelde K . Drug-induced hepatitis: a rare complication of oral anticoagulants. J Hepatol. 1994; 21(3):447-9. DOI: 10.1016/s0168-8278(05)80326-5. View

3.

Woolley S, Burger H, Zellweger U . [Phenprocoumon-induced cholestatic hepatitis]. Dtsch Med Wochenschr. 1995; 120(44):1507-10. DOI: 10.1055/s-2008-1055506. View

4.

Perzborn E, Kubitza D, Misselwitz F . Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders. Hamostaseologie. 2007; 27(4):282-9. View

5.

Camm A, Kirchhof P, Lip G, Schotten U, Savelieva I, Ernst S . Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010; 31(19):2369-429. DOI: 10.1093/eurheartj/ehq278. View

6.

Agnelli G, Gallus A, Goldhaber S, Haas S, Huisman M, Hull R . Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation. 2007; 116(2):180-7. DOI: 10.1161/CIRCULATIONAHA.106.668020. View

7.

Patel M, Mahaffey K, Garg J, Pan G, Singer D, Hacke W . Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883-91. DOI: 10.1056/NEJMoa1009638. View

8.

Neef M, Kerekes Z, Fischer H, Sauerbruch T, Spengler U . Acenocoumarol is not a safe alternative for anticoagulation in phenprocoumon-induced hepatic failure. Report of two cases. Digestion. 2003; 67(1-2):100-4. DOI: 10.1159/000070397. View

9.

Mix H, Wagner S, Boker K, Gloger S, Oldhafer K, BEHREND M . Subacute liver failure induced by phenprocoumon treatment. Digestion. 1999; 60(6):579-82. DOI: 10.1159/000007710. View

10.

Fuster V, Ryden L, Cannom D, Crijns H, Curtis A, Ellenbogen K . ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology.... Eur Heart J. 2006; 27(16):1979-2030. DOI: 10.1093/eurheartj/ehl176. View

[Unclear Hepatopathy in a Patient with Atrial Fibrillation]